|
---|
Category:Report
MONTHYEARML24282B0122024-10-29029 October 2024 NRC Report for September 2024 SRS Sdf Oov ML24213A0202024-10-21021 October 2024 Final Supporting Statement for 10 CFR Part 31 General Domestic Licenses for Byproduct Material (3150-0016) ML24289A0932024-10-0404 October 2024 ACMUI 2024 Bylaws Subcommittee Draft Report October 4, 2024 ML24274A1922024-09-30030 September 2024 GEH Vallecitos Boiling Water Reactor License Termination Plan Environmental Assessment ML24275A0752024-09-30030 September 2024 TLR-RES/DE/REB-2024-16, Integration of Safety, Security, and Safeguards During Design and Operations - a Technical Assessment and Regulatory Considerations for Advanced Reactor and Advanced Fuel Fabrication Facilities ML24270A1282024-09-26026 September 2024 Licensing Actions Received Month of March 2024 ML24256A1702024-09-19019 September 2024 Results of the NRCs Section 610 Review of the Physical Protection of Byproduct Material ML22035A0822024-08-23023 August 2024 SA-300 Handbook Comment Resolution - External ML24053A1032024-08-22022 August 2024 Final Rule ASME 2021-2022 Congressional Review Act Summary ML24221A1452024-08-0808 August 2024 ACMUI Subcommittee on Financial Assurance Draft Report, August 8 2024 ML24185A2682024-07-0303 July 2024 ACMUI Training and Experience (T&E) for All Modalities Subcommittee Final July 3, 2024 ML24214A3272024-04-30030 April 2024 Environmental Assessment and Finding of No Significant Impact for the Construction Permits for the Kairos Hermes 2 Test Reactors - Draft Report for Comment ML24120A2452024-04-24024 April 2024 ACMUI Spring 2024 Eye90 Subcommittee Final Report, Dated April 24 2024 ML24106A0982024-04-15015 April 2024 Advisory Committee on the Medical Uses of Isotopes (Acmui), Akesis Galaxy Rti Draft Licensing Guidance, Final Report, April 15, 2024 ML24116A2572024-03-16016 March 2024 Subcommittee on Yttrium-90 Microsphere Brachytherapy Eye90 Microspheres Device, Dated March 16 2024, Draft Report ML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23338A2572023-12-14014 December 2023 Kairos Power LLC - Summary Record of Decision ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML23229A2272023-11-0909 November 2023 Response to SRM-M230814 - Rulemaking - Final Rule - Comment Response Document - Emergency Preparedness for Small Modular Reactors and Other New Technologies ML22354A2652023-11-0808 November 2023 2. Proposed CoC No. 1026, Renewed Amendment No. 0 ML22354A2692023-11-0808 November 2023 6. Proposed CoC No. 1026, Renewed Amendment No. 1 ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23194A1352023-09-0707 September 2023 OMB 3150-0007, Final Supporting Statement for 10 CFR Part 34, Licenses for Radiography and Radiation Safety Requirements for Radiographic Operations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22271A8622023-03-24024 March 2023 OMB-3150-0017 Final Supporting Statement for 10 CFR Part 30 Rules of General Applicability to Domestic Licensing of Byproduct Material ML22320A0752023-02-28028 February 2023 Draft Supporting Statement- Requests to Indian Tribes for Information (3150-0245) ML22318A1272023-01-0303 January 2023 Final OMB Supporting Statement: NRC Form 314 ML22133A0462022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Backfitting and Issue Finality Assessment for Fitness for Duty Drug Testing Requirements ML22133A0522022-11-10010 November 2022 Response to SRM-M220323: Final Rule-Response to Public Comments for Fitness for Duty Drug Testing Requirements SECY-20-0109, Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking2022-11-0404 November 2022 Rulemaking: Regulatory Basis for Reporting Requirements for Nonemergency Events at Nuclear Power Plants Rulemaking ML21267A0942022-09-30030 September 2022 Rulemaking: Final Rule: Comment Response Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML21267A0982022-09-30030 September 2022 Rulemaking: Final Rule: Annotated Public Comments Document: Incorporate by Reference American Society of Mechanical Engineers Boiler and Pressure Vessel Code and Operations and Maintenance Code ML22117A2072022-08-16016 August 2022 OMB 3150-0120, Supporting Statement Draft for NRC Form 313 Application for Materials License, and NRC Forms 313A ML22201A5012022-07-26026 July 2022 U.S. Nuclear Regulatory Commission Sustainability Report and Implementation Plan 2022 ML22165A1662022-07-20020 July 2022 OMB 3150-0055, Final Supporting Statement for Title 10 of the Code of Federal Regulations Part 75 Safeguards on Nuclear Material - Implementation ML22130A1542022-07-0707 July 2022 Final OMB Supporting Statement for 10 CFR Part 150 Exemptions and Continued Regulatory Authority in Agreement States and Offshore Waters ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22084A6102022-04-11011 April 2022 NRC Communication with American Board of Health Physics (Abhp) in 2019 Thru 2022 ML21196A1002022-03-0202 March 2022 Rulemaking: Final Rule: Comment Response Document American Society of Mechanical Engineers Code Cases RG 1.84, Rev 39; RG 1.147, Rev 20; and RG 1.192, Rev 4 ML22032A0012022-02-28028 February 2022 Rulemaking; Proposed Rule; Unofficial Redline Rule Language for the Proposed Rule - Regulatory Improvements for Production and Utilization Facilities Transitioning to Decommissioning ML22200A2692022-02-0202 February 2022 5Q1.2-302, Rev. 31, Proceduradiation Monitoring - Water Sampling Analysis ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21350A4522021-12-15015 December 2021 Enclosure - Materials RAI Response Clarifications ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 2024-09-30
[Table view]Some use of "" in your query was not closed by a matching "". Category:Technical
MONTHYEARML24274A1922024-09-30030 September 2024 GEH Vallecitos Boiling Water Reactor License Termination Plan Environmental Assessment ML24275A0752024-09-30030 September 2024 TLR-RES/DE/REB-2024-16, Integration of Safety, Security, and Safeguards During Design and Operations - a Technical Assessment and Regulatory Considerations for Advanced Reactor and Advanced Fuel Fabrication Facilities ML24256A1702024-09-19019 September 2024 Results of the NRCs Section 610 Review of the Physical Protection of Byproduct Material ML24214A3272024-04-30030 April 2024 Environmental Assessment and Finding of No Significant Impact for the Construction Permits for the Kairos Hermes 2 Test Reactors - Draft Report for Comment ML24120A2452024-04-24024 April 2024 ACMUI Spring 2024 Eye90 Subcommittee Final Report, Dated April 24 2024 ML24018A1152024-01-19019 January 2024 Acu Msrr - Historic and Cultural Resources ML23333A0142023-11-27027 November 2023 Attachment F - Groundwater Tek Inc - Peer Review Study Final-1 ML23333A0172023-11-27027 November 2023 Attachment I - Chin - the Cooling Canal System at the FPL-Turkey-Point Power Station ML22354A2652023-11-0808 November 2023 2. Proposed CoC No. 1026, Renewed Amendment No. 0 ML22354A2692023-11-0808 November 2023 6. Proposed CoC No. 1026, Renewed Amendment No. 1 ML23251A0462023-09-30030 September 2023 Technical Report - Review of Documents Related to Tank 12H Grout Formulations ML23192A7672023-08-21021 August 2023 Intercontinental Energy Corporation Final Completion Review Report Review and Approval ML22353A5992023-06-21021 June 2023 Enclosure - NMSS VLSSIR Wg Report and Implementation Guidance ML23097A1712023-05-0808 May 2023 Review of New and Potentially Significant Information for the Holtec Environmental Impact Statement for a Consolidated Interim Storage Facility for Spent Nuclear Fuel in Lea County, New Mexico ML22178A0662022-05-24024 May 2022 SRMC-CWDA-2022-00006, Rev. 0, Fiscal Year 2022 Savannah River Site Liquid Waste Facilities Performance Assessment Maintenance Program ML22021B2992022-01-21021 January 2022 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39, Release of Patients Administered Radioactive Materials, Review and Comment on the Draft Civaderm Device Licensing Guidance, Final Report, January 21, 2022 ML21280A1032021-12-0606 December 2021 Updated Biological Assessment of Impacts to Federally Listed Species Under NMFS Jurisdiction for SONGS Decommissioning ML21341A5592021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comments on the Draft Civaderm Device Licensing Guidance, Draft Report, December 1, 2021 ML21341A5642021-12-0101 December 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on RG 8.39 Release of Patients Administered Radioactive Materials, Review and Comment on Draft Proposed Revision 2 to Regulatory Guide 8.39, Draft Report, December 15, ML21341A5612021-11-29029 November 2021 Advisory Committee on the Medical Uses of Isotopes (Acmui), Subcommittee on Alpha Dart, Review and Comment on Draft Licensing Guidance Alpha Tau Alpha Dart Manual Brachytherapy, Draft Report, December 15, 2021 ML21294A3422021-11-24024 November 2021 COVID-19 Public Health Emergency Oversight Activities Assessment Phase B Report ML21172A2822021-10-19019 October 2021 Physical Security Requirements for Category II Fuel Cycle Facilities Information Sheet (HALEU Related) ML21287A6312021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics Subcommittee, Final Report, October 14, 2021 ML21288A1262021-10-14014 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Final Report, October 14, 2021 ML22012A0702021-10-0404 October 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Events, Draft Report, October 4, 2021 ML22012A0652021-09-20020 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Emerging Radiopharmaceutical Therapy Knowledge Requirements in Theranostics, Draft Report, September 20, 2021 ML22012A0672021-09-0808 September 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Radionuclide Generator Knowledge and Practice Requirements, Draft Report, September 8, 2021 ML21232A5432021-08-20020 August 2021 Advanced Reactors Details Website ML21210A3512021-07-30030 July 2021 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Extravasations, Review and Comments on the Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting, Draft Report, July 30, 2021 ML21085A7472021-04-30030 April 2021 Glwg Agreement State Survey Summary ML21144A1192021-04-0808 April 2021 RA-136-Reclassified ML21144A1202021-04-0808 April 2021 RA-432-Reclassified ML21144A1222021-04-0808 April 2021 SYP-233-Reclassified ML20133J9292020-05-18018 May 2020 Enclosure 1, Technical Evaluation Review of Decommissioning Funding Plan (Publicly Available) ML20128J8322020-05-11011 May 2020 Technical Evaluation Report for the Draft Wir Evaluation for Closure of Wma C at Hanford Site, Washington ML20079E0862020-03-0202 March 2020 Necr B8 Wb (002) ML20079E0892020-03-0202 March 2020 Reply to Arlt Comments 3-2-2020 Draft (002) ML20075A0292020-03-0202 March 2020 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Bylaws Subcommittee, Draft Report, March 2, 2020 ML19297E7912019-10-23023 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Final Report, October 23, 2019 ML19280D1632019-10-0606 October 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Comments on the Draft Evaluation of Training & Experience Requirements for Radiopharmaceuticals Secy Paper, Draft Report, October 6, 2019 ML19297E6942019-08-28028 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on the Appropriateness of Medical Event Reporting, Draft Report, August 28, 2019 ML19297E9022019-08-21021 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on Medical Event Reporting, Review of FY2018, Draft Report, August 21, 2019 ML19296D1202019-08-0808 August 2019 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Subcommittee on ACMUI Institutional Memory, Draft Report, August 8, 2019 ML19106A3672019-07-25025 July 2019 Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance ML19162A2592019-07-22022 July 2019 Technical Analyses of the Hazards of Disposal of Greater-Than-Class C (GTCC) Waste ML19198A2522019-06-20020 June 2019 Alternate Disposal Request - Rail Shipments (License DPR-28, Docket No. 50-271) ML18061A0502018-12-31031 December 2018 U.S. Nuclear Regulatory Commission Staff Responses to Public Comments on Proposed Rule: Amendments to Material Control and Accounting Regulations and Associated Draft Guidance ML18164A0712018-09-20020 September 2018 Us Ecology Idaho Site-Specific Dose Assessment Rev. 3 - TER (Public) ML18204A2142018-08-28028 August 2018 Enclosures 1-6: Pssc Multiple Closure ML18071A4132018-02-27027 February 2018 Advisory Committee on the Medical Uses of Isotopes (ACMUI) Physical Presence Requirements for the Leksell Gamma Knife Icon, Final Report, February 27, 2018 2024-09-30
[Table view]Some use of "" in your query was not closed by a matching "". |
Text
U.S Nuclear Regulatory Commission Advisory Committee on the Medical Uses of Isotopes
Subcommittee on Radionuclide Generator Knowledge and Practice Requirements
Draft Report Submitted on September 8, 2021
Subcommittee Members:
Vasken Dilsizian, M.D.
Richard Green (Chair)
Melissa Martin Megan Shober Harvey Wolkov, M.D.
NRC Staff Resource: Maryann Ayoade
Subcommittee Charge:
- To review and evaluate the knowledge and practice requirements for eluting, measuring and testing, and processing the eluate from radionuclide generator systems based on the evolution of radionuclide generator distribution.
- To evaluate and determine the appropriateness of the requireme nts and how best to obtain the required knowledge and practice.
- To evaluate whether and how additional knowledge and practice should be obtained as necessary to supervise the use of any radionuclide generator sy stem.
- Provide considerations and recommendations to staff.
Background:
In 1994, the NRC amended its commercial distribution of radioac tive drugs and medical use regulations in 10 CFR Parts 32 and 35, in part, to allow proper ly qualified nuclear pharmacists and authorized users who are physicians with greater discretion in preparing radioactive drugs containing byproduct material for medical use. The rule, Prep aration, Transfer for Commercial Distribution, and Use of Byproduct Material for Medical Use, r esulted in the language presently found in 10 CFR 35.290, Training for imaging and localization studies. Specifically, 10 CFR 35.290(c)(1)(ii)(G) relative to generators reads:
(G) Eluting generator systems appropriate for preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs;
Over the last 27 years, the types of radionuclide generators us ed in clinical nuclear medicine practice, the location where they are housed and used, and the individuals who handle them have all significantly changed.
Molybdenum-99/Technetium-99m (99Mo/99mTc) generators
Prior to 1972, 99Mo/99mTc generators were ubiquitous and were found in every clinical nuclear medicine facility. The first cent ralized radiopharmacy (CRP) opened in 1972 and today there are approximately 300 centralized radiopharmacies in the United Sta tes. Over the course of time, the locations of most 99Mo/99mTc generators migrated from hospital nuclear medicine departmen ts to CRPs as nuclear medicine facilities converted to patient ready unit doses and utilized the services of CRPs for the provision of radiopharmaceuticals. Today approximately 95% of all radiopharmaceuticals used in the United States originate from a CRP. As a result of the consolidation of activities, there are fewer 99Mo/99mTc generators in use today than were used in the past. It is estimated that the United States utilizes appr oximately 720 new 99Mo/99mTc generators weekly, with 90% of them (~660) delivered to CRPs fo r use under the direction of an authorized nuclear pharmacist (ANP) and 10% of them (~60) deliv ered to hospital facilities for use under the direction of an authorized user (AU) physician or loc al ANP.
Strontium-82/Rubidium-82 (82Sr/82Rb) generators
Because of the 75 second half-life of 82RbCl2 used for PET myocardial perfusion imaging, all 82Rb generators are in clinical nuclear medicine facilities for use under the direction of an AU physician.
Germanium-68/Gallium-68 (68Ge/68Ga) generators
It is estimated that currently in the United States, approximat ely 70% of 68Ge/68Ga generators are delivered to CRPs for use under the direction of an ANP and 30% are delivered to hospital facilities for use under the direction of an AU physician.
The evolution of where radionuclide generators are located has presented challenges for fellows-in-training in residency programs. Many residency programs had made arrangements with commercial radiopharmacies for their fellows-in-training to att end generator training but due to COVID-19 these radiopharmacies have restricted access to their facilities. This increased the knowledge and practice burden affecting fellows-in-training who were unable to attend commercial radiopharmacies to receive generator training due to COVID-19 closures of these facilities.
In June 2020, several professional societies (American Society of Nuclear Cardiology, Society of Nuclear Medicine and Molecular Imaging, American College of Rad iology, and the American Society for Radiation Oncology) united to request that the U.S. Nuclear Regulatory Commission (NRC) consider Title 10 of the Code of Federal Regul ations (10 CFR) 35.290(c)(1)(ii)(G), Training for Imaging and Localization Stu dies, as a potential area for regulatory relief during the Coronavirus Disease 2019 (COVID-19 ) Public Health Emergency (PHE). This letter states that most of the commercial radiopha rmacies that supply portions of this training are closed to visiting trainees because of the CO VID-19 PHE and may not reopen for the foreseeable future. This letter further states that the y believe that this experience requirement can be satisfied virtually, via demonstrative educa tional webinars during the duration of the public health emergency. (Agencywide Documents Access and Management System [ADAMS] Accession No. ML20231A931).
Discussion:
The Subcommittee deliberated the intent of the existing Rule la nguage, the knowledge elements necessary for authorized user physicians to possess with regard to generator systems, and various methods of acquiring knowledge of these elements. The S ubcommittee recognizes the authorized user physicians role, as described in 10 CFR 35.27, supervising nuclear medicine technologists who may be operating generator systems at clinica l sites. Consequently, the Subcommittee believes that authorized users, whether or not the y personally use radionuclide generators, must be familiar with how generators work, how brea kthrough is tested, and how reagent kits are used to label radioactive drugs. The Subcommit tee also believes that it is not necessary for authorized user physicians to have direct hands-o n work experience with the generators, although the Subcommittee recognizes that direct wo rk experience is an excellent way to fulfill the training requirements.
In order to facilitate learning, and to provide training progra ms flexibility to deliver training, the Subcommittee discussed the strengths and limitations of in-pers on, pre-recorded, or live virtual training opportunities. The Subcommittee believes that training can incorporate any combination of these methods, but the Subcommittee believes it is essential for the training to include an opportunity for physicians to ask questions about the subject m aterial and receive answers in real time. In addition, it is important for the trainer to be able t o assess physician learning as the training is progressing. If pre-recorded material is used to de liver a portion of the training, there should also be a live component (whether in-person or via virtu al meeting) where trainees and trainers can directly interact.
Consistent with existing regulation, the Subcommittee further b elieves that it is not necessary to mandate training on every radionuclide generator system. Training programs should have t he flexibility to modify the training curriculum as the use of gen erator systems evolves.
Conclusion - Subcommittee Recommendation:
Current rule language in 10 CFR 35.290(c)(1)(ii)(G):
(G) Eluting generator systems appropriate for preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs;
Subcommittee proposed revision:
(G) Participating in educational sessions to gain knowledge and provide supervision of -
(1) radionuclide generator systems and their operation; (2) the measurement of radionuclidic impurities and acceptable limits; and (3) the use of reagent kits with radionuclide eluate to prepare radioactive drugs.
Respectfully Submitted on September 8, 2021 Radionuclide Generator Knowledge and Practice Requirements Subc ommittee Advisory Committee on the Medical Uses of Isotopes (ACMUI)
U.S. Nuclear Regulatory Commission (NRC)